Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea · Delayed Price · Currency is KRW 7,120.00
-520.00 (-6.81%)
At close: Apr 2, 2026
Kyongbo Pharmaceutical Revenue
In the year 2025, Kyongbo Pharmaceutical had annual revenue of 264.10B KRW with 10.71% growth. Kyongbo Pharmaceutical had revenue of 71.22B in the quarter ending December 31, 2025, with 20.07% growth.
Revenue
264.10B
Revenue Growth
+10.71%
P/S Ratio
0.69
Revenue / Employee
n/a
Employees
n/a
Market Cap
182.65B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 264.10B | 25.55B | 10.71% |
| Dec 31, 2024 | 238.56B | 22.20B | 10.26% |
| Dec 31, 2023 | 216.36B | 20.09B | 10.24% |
| Dec 31, 2022 | 196.26B | 25.61B | 15.00% |
| Dec 31, 2021 | 170.66B | -44.63B | -20.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jeil Pharmaceutical Co.,Ltd | 567.24B |
| Dongwha Pharm.Co.,Ltd | 496.39B |
| Ilyang Pharmaceutical Co.,Ltd | 272.42B |
| JW Lifescience | 257.83B |
| Whan In Pharm | 255.21B |
| Daihan Pharmaceutical | 208.61B |
| REYON Pharmaceutical | 149.34B |
| Hana Pharm | 139.33B |